INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 23 Normanby Rd, Notting Hill,victoria 3168,australia
- Industry
- Biotechnology
- Website
- http://www.inoviq.com
- Keywords
- Cancer Diagnostics, Cancer Biomarkers, Exosomes, Extracellular Vesicles, Diagnostics, Exosome Therapeutics, Exosome Diagnostics, Exosome Isolation, Cancer screening, Cancer monitoring, Companion diagnostics.
- HQ
- Notting Hill, Victoria
Inoviq Ltd (Asx:iiq) Questions
Inoviq Ltd (Asx:Iiq)'s website is http://www.inoviq.com
Inoviq Ltd (Asx:Iiq)'s LinkedIn profile is https://au.linkedin.com/company/inoviq
Inoviq Ltd (Asx:Iiq) has
22 employees.
View email and phone details for 22
employees at Inoviq Ltd (Asx:Iiq).
Inoviq Ltd (Asx:Iiq)'s industry is
Biotechnology
Inoviq Ltd (Asx:Iiq)'s top competitors are
Incora Health,
Exopharm Ltd,
Omada Health,
Sienna Cancer Diagnostics - A Bard1 Life Sciences Company,
Culturon®,
Prescient Therapeutics,
Anteotech Ltd,
Sociability,
Rhythm Biosciences Limited,
Emyria (Asx:emd).
Inoviq Ltd (Asx:Iiq)'s categories are Biotechnology
Inoviq Ltd (Asx:Iiq)'s founding year is 2016
